The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon
- PMID: 18407321
- DOI: 10.1016/j.thromres.2008.01.020
The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon
Abstract
Introduction: Vitamin K antagonists of the coumarin type are widely used oral anticoagulants.
Objective: We developed a transition algorithm for the maintenance dosages of three frequently used coumarins: warfarin, phenprocoumon and acenocoumarol.
Methods: The study was conducted at the Leiden Anticoagulation Clinic. Patients were participants in a trial of which the main objective was to compare the quality of an oral anticoagulant therapy with phenprocoumon to warfarin. We included patients who initiated oral anticoagulant therapy and patients who were already using acenocoumarol. Patients were randomized to a treatment with warfarin or phenprocoumon. Patients who were randomized to warfarin switched to phenprocoumon at the end of follow-up. We analysed the switch from acenocoumarol to warfarin or phenprocoumon at the start of follow-up and the switch of warfarin to phenprocoumon at the end of follow-up and calculated the transition factors for stable anticoagulation between these three vitamin K antagonists.
Results: Fifty-eight patients switched from warfarin to phenprocoumon, 39 from acenocoumarol to phenprocoumon and 44 from acenocoumarol to warfarin. The maintenance dose of warfarin was 0.41 (95%CI 0.39-0.43) times the maintenance dose of phenprocoumon. The transition factor between acenocoumarol and phenprocoumon was 0.84 (95%CI 0.79-0.89) and between acenocoumarol and warfarin 1.85 (95%CI 1.78-1.92).
Conclusions: We determined the transition factors between warfarin, phenprocoumon and acenocoumarol. With these transition factors physicians are able to estimate the maintenance dose when it is necessary for a patient to switch from one coumarin to the other.
Similar articles
-
Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?Thromb Haemost. 1998 Dec;80(6):899-902. Thromb Haemost. 1998. PMID: 9869157 Clinical Trial.
-
Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.Thromb Haemost. 2007 Oct;98(4):747-55. Thromb Haemost. 2007. PMID: 17938797
-
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.Clin Pharmacokinet. 2005;44(12):1227-46. doi: 10.2165/00003088-200544120-00003. Clin Pharmacokinet. 2005. PMID: 16372822 Review.
-
Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial.Arch Intern Med. 2003 Nov 24;163(21):2639-46. doi: 10.1001/archinte.163.21.2639. Arch Intern Med. 2003. PMID: 14638565 Clinical Trial.
-
[Oral anticoagulation with vitamin K antagonists].Ther Umsch. 2003 Jan;60(1):5-9. doi: 10.1024/0040-5930.60.1.5. Ther Umsch. 2003. PMID: 12638470 Review. German.
Cited by
-
A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.J Appl Genet. 2009;50(4):399-403. doi: 10.1007/BF03195700. J Appl Genet. 2009. PMID: 19875892
-
Unintentional ingestion of a high dose of acenocoumarol in a young child.BMJ Case Rep. 2021 Apr 1;14(4):e240365. doi: 10.1136/bcr-2020-240365. BMJ Case Rep. 2021. PMID: 33795273 Free PMC article.
-
Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.Eur J Drug Metab Pharmacokinet. 2012 Jun;37(2):125-32. doi: 10.1007/s13318-011-0056-7. Epub 2011 Aug 3. Eur J Drug Metab Pharmacokinet. 2012. PMID: 21811894
-
Practical Suggestions for an Optimal Management of Vitamin K Antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper.Thromb Haemost. 2024 Aug;124(8):803-809. doi: 10.1055/s-0044-1782688. Epub 2024 Apr 16. Thromb Haemost. 2024. PMID: 38626900 Free PMC article. Review.
-
Determining Drug Exposure Based on Medication Dispensing Data: A Validation Study of Vitamin K Antagonist Treatment Episodes Against INR Records.Pharmacoepidemiol Drug Saf. 2025 Jun;34(6):e70158. doi: 10.1002/pds.70158. Pharmacoepidemiol Drug Saf. 2025. PMID: 40389391 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical